LSTA: רווח למניה בשנים עשר החודשים האחרונים lisata.com

Lisata Therapeutics (LSTA) relies on external contractors to conduct clinical trials, focusing on the protection of its patents. The annual earnings per share trend shows that the parameter has stabilized at -1.88, while the company minimizes capital expenditures through production outsourcing. Drug development is based on an ecosystem approach to tumor therapy in collaboration with pharmaceutical behemoths.
Lisata (LSTA) - פילוחי מדדים ודוחות פיננסיים

Earnings per share (EPS TTM) determines the actual equity value of business income over a trailing twelve-month period. This metric neutralizes the impact of security issuance, allowing for an assessment of fundamental profit generation efficiency. By analyzing changes in TTM net income per share, an investor identifies the company's long-term growth trajectory. For Lisata Therapeutics (LSTA), this indicator reflects financial stability during the development of the CendR platform. Success in pancreatic cancer therapy trials will directly determine the future dynamics of this metric.